Effect of Heparin and Heparin Fractions on Platelet Aggregation

Salzman, Edwin W.; Rosenberg, Robert D.; Smith, M.H.; Lindon, Jack N.; Favreau, Leonard

doi:10.1172/jci109661

Cited by 622 publications

(224 citation statements)

References 47 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…Thrombocytopenia of this type is mild (platelet count, >100 x 10 9 cells/L), not progressive, nor associated with bleeding or thrombosis (Salzman et al, 1980), and is independent of any immune reaction (Chong et al, 1993a;Burgess & Chong, 1997;Shantsila et al, 2009). It is characterized by a transitory, slight and asymptomatic reduction in platelet count, occurring during the first 1-2 days of heparin administration.…”

Section: Intoductionmentioning

confidence: 99%

Heparin-Induced Thrombocytopenia

Nakamura¹

2012

Hematology - Science and Practice

View full text Add to dashboard Cite

Section: Intoductionmentioning

confidence: 99%

Heparin-Induced Thrombocytopenia

Nakamura¹

2012

Hematology - Science and Practice

View full text Add to dashboard Cite

“…Heparin binds to platelets, activating platelet factor IV and stimulating its release (Salzman et al, 1980). Then, heparin creates a complex with platelet factor IV, stimulating antibodies primarily responsible for thrombocytopenia (Kelton et al, 1994).…”

Section: Heparin-induced Thrombocytopenia -Hitmentioning

confidence: 99%

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Dvořák¹,

Vlašín²,

Dvorakova³

et al. 2010

Vet. Med. - Czech

View full text Add to dashboard Cite

Arterial occlusion due to thrombosis caused by ruptured atherosclerotic plaques (Baba et al., 1975) has been recognized as a major cause of morbidity and mortality in western populations. Thrombosis may occur in various sections of arterial circulation, peripheral arteries of the limbs, coronary arteries, brain arteries, or both major and minor vessels within the abdominal cavity. The ultimate consequence is varying degrees of organ failure, mostly of ischemic origin. Arterial thrombosis represents a continuous problem, debilitating patients and decreasing their quality of life. Moreover, along with chronic heart failure, it can significantly decrease patient life expectancy. Arterial thrombosis results in ischemia, with serious systemic consequences, such as metabolic breakdown. The major goal of treatment remains fast and efficient recanalization -surgical, interventional or thrombolytic. To be able to prevent acute reocclusion with severe consequences (rhabdomyolysis, compartment syndrome, excessive tissue necrosis leading to limb amputation, etc.), several adjunctive treatment regimens have been advocated. Among others, thrombin inhibitors and platelet inhibitors have been widely used for both prophylaxis and adjunctive treatment. Direct thrombin inhibitors and antithrombin stimulators have been recognized as typical antithrombotic drugs. Direct (antithrombin-independent) thrombin inhibitors can be divided into two main categories: monovalent, active site inhibitors (argatroban, efegatran, inovastan, melagatran) and bivalent (hirudin, hirugen, hirulog, bivalirudin), while antithrombin stimulators represent standard (unfractionated) heparin (UFH) and its depolymerizing products -low molecular weight heparins (LMWH's). Recently, a clear change in the main use of heparin, as well as low-molecular weight heparins has been advocated representing a shift from treatment and prophylaxis of deep vein thrombosis to prophylaxis of thromboembolic disease following vascular, cardiovascular or orthopedic surgery, treatment of unstable angina and prevention of acute myocardial infarction. The main effect of heparins lies in their anticoagulant activity. Heparins are involved in different pathways of the coagulation cascade with anticoagulant, antithrombotic, profibrinolytic, anti-aggregative, as well as anti-inflammatory effects. Moreover, there is a little doubt about their anti-proliferative and anti-ischemic activity (Penka and Bulikova, 2006). Unlike standard heparin, low-molecular weight heparins do not affect the patient's general coagulation profile. Obviously, the difference in molecular weight results in different pharmacokinetic and pharmacodynamic properties of the agents.Key words: coagulation; arterial thrombosis; standard heparin; low-molecular weight heparins List of abbreviations ABI = axillary/...index, t-PA = tissue-type plasminogen activator, ADP = adenosin diphosphate, AG = angiography, AMI = acute myocardial infarction, APSAC = acylated plasminogen streptokinase activator complex, APTT = acti...

show abstract

“…Danaparoid is also known to have potent anticoagulant activity similar to that of heparin, [4], [5] although platelet aggregation was in some cases observed in blood with heparin [6]- [8] due to unclarified mechanism.…”

Section: Introductionmentioning

confidence: 99%

“…[9] Danaparoid would be then a promising antico- control. [8] PRP was pre-incubated for one minute in the incubating hole of the aggregometer. Automated blood counting Heparin (22.5 U) or Danaparoid (22.5 U) was placed in plastic test tubes as an anticoagulant, and 1 mL of whole blood was added to the tubes in duplicate.…”

Section: Introductionmentioning

confidence: 99%

Availability of Danaparoid, an Anticoagulant, for Routine Hematological Tests.

Tatsumi

Nishioka

Yokota

et al. 2003

HEP

View full text Add to dashboard Cite

In the Multiphasic Health Check-up System, medical laboratory testing has been changing lately to utilize a small and compact type of testing systems. The system uses heparinized blood for chemistry tests to reduce laboratory's workload and sample volume. The danaparoid, a mixture of glycosamino-glycans (Heparan sulfate), has been used clinically for treatment of patients with disseminated intravascular coagulopathy instead of heparin sulfate. Heparin has been used for routine laboratory tests, although it has a strong activity of platelet aggregation. This study aimed to examine availability of Danaparoid for routine hematology tests as a substitute of heparin. Although Danaparoid induced platelet aggregation directly, the reaction was weaker than that of heparin. The platelet count of Danaparoid blood was decreased after five minutes of mixing. Addition of MgSO4 or of kanamycin sulfate to Danaparoid blood was able to prevent this decrease. When Danaparoid blood was applied to chemistry tests, major chemistry test data showed acceptable results, although level differences were observed slightly. It was concluded that Danaparoid would be a good candidate for a universal anticoagulant for both chemical and hematological laboratory tests.

show abstract

Effect of Heparin and Heparin Fractions on Platelet Aggregation

Cited by 622 publications

References 47 publications

Heparin-Induced Thrombocytopenia

Heparin-Induced Thrombocytopenia

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Availability of Danaparoid, an Anticoagulant, for Routine Hematological Tests.

Contact Info

Product

Resources

About